These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3243982)

  • 1. CA 19-9 assay in patients with extrahepatic cholestatic jaundice.
    Barone D; Onetto M; Conio M; Paganuzzi M; Saccomanno S; Aste H; Pugliese V
    Int J Biol Markers; 1988; 3(2):95-100. PubMed ID: 3243982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
    Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
    Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Laboratory diagnosis of tumors of the pancreato-biliary area in patients with mechanical jaundice].
    Skvortsov SV; Lytsar' BN; Kalinin AV; Dolinskiĭ AG
    Klin Med (Mosk); 1992; 70(5-6):21-3. PubMed ID: 1279265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
    Mann DV; Edwards R; Ho S; Lau WY; Glazer G
    Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Is jaundice a cause of error in the interpretation of CA 19-9 blood levels?].
    Nakad A; Colombel JF; Geubel AP; Cerulus G; Farchakh E; Degrez T; Janssen J; Cortot A; Paris JC; Dive C
    Acta Gastroenterol Belg; 1989; 52(1-2):17-22. PubMed ID: 2618531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
    Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
    Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease.
    Kim MS; Jeon TJ; Park JY; Choi J; Shin WC; Park SE; Seo JY; Kim YM
    Korean J Gastroenterol; 2017 Aug; 70(2):96-102. PubMed ID: 28830135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.
    La Greca G; Sofia M; Lombardo R; Latteri S; Ricotta A; Puleo S; Russello D
    World J Gastroenterol; 2012 Aug; 18(31):4150-5. PubMed ID: 22919247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of ultrasound, computed tomography and endoscopic retrograde cholangiopancreatography in the differential diagnosis of benign and malignant jaundice and cholestasis.
    Pasanen PA; Partanen KP; Pikkarainen PH; Alhava EM; Janatuinen EK; Pirinen AE
    Eur J Surg; 1993 Jan; 159(1):23-9. PubMed ID: 8095802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases.
    Pålsson B; Masson P; Andrén-Sandberg A
    Scand J Gastroenterol; 1993 Nov; 28(11):981-7. PubMed ID: 8284635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
    Haglund C; Roberts PJ; Kuusela P; Scheinin TM; Mäkelä O; Jalanko H
    Br J Cancer; 1986 Feb; 53(2):197-202. PubMed ID: 3456787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dilemma of elevated CA 19-9 in biliary pathology.
    Tsen A; Barbara M; Rosenkranz L
    Pancreatology; 2018 Dec; 18(8):862-867. PubMed ID: 30249386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical significance of CA 50 assay as a tumor marker].
    Hara K; Mitsuhashi F; Ohkura H
    Nihon Rinsho; 1990 Feb; 48 Suppl():971-3. PubMed ID: 2192182
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
    Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis of cancer of the organs of the pancreatoduodenal zone accompanied by jaundice].
    Kasum'ian SA; Cherniavskiĭ AA; Troitskiĭ KI; Shitov AN; Mezinov VV
    Khirurgiia (Mosk); 1988 Nov; (11):65-8. PubMed ID: 3210627
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor markers in pancreatic cancer: a comparative clinical study between CEA, CA 19-9 and CA 50.
    Molina LM; Díez M; Cava MT; Maestro ML; Ortega MD; Mendíz JG; Prego A; De Diego JA; Balibrea JL
    Int J Biol Markers; 1990; 5(3):127-32. PubMed ID: 2286776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.